Tackling the Serious Global Challenges in Infectious Disease

Appili was created to deliver innovative drug development programs for unmet patient needs across a broad spectrum of infectious diseases

Advancing infectious disease drug development programs to provide solutions to patients, doctors, and society.

Leadership team skilled in advancing programs with upside potential

Active partnering and in-licensing efforts to expand clinical programs and accelerate commercialization

Appili Therapeutics: Innovation Across a Broad Spectrum of Anti-Infectives


Appili Therapeutics to Present at the 2021 VIRTUAL H.C. Wainwright BioConnect Conference
Dr. Reddy's Laboratories, Global Response Aid, and Appili Therapeutics Announce the Filing of an Application for REEQONUS™ (Favipiravir) Tablets for the Treatment of COVID-19 Under Health Canada’s Interim Order
First Patient Dosed in Appili Therapeutics’ Phase 3 Clinical Trial of Avigan® Tablets (Favipiravir) for the Treatment of COVID-19 in the United States